


Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-21 (Cancelled).

Claim 22 (New): A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:



Formula (I)

wherein:

X is S;

R¹ is optionally substituted furan-C₁alkyl;

R² is optionally substituted Ar-C₀₋₆alkyl; and

R³ is H, optionally substituted C₁₋₆alkyl, C₃₋₆alkenyl, or C₃₋₆alkynyl.

Claim 23 (New): The compound according to claim 22, selected from:

5-(5-phenylamino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carbaldehyde;
5-(5-p-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester;
5-(5-p-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carbaldehyde;
5-(5-o-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester;
5-(5-o-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester
3-(2-methoxy-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(3-methylphenylamino)-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4H-[1,2,4]triazol-3-ylsulfanyl methyl)-furan-2-carboxylic acid ethyl ester;

5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde; and
3-(4-fluoro-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole
or a pharmaceutically acceptable salt or solvate thereof.

Claim 24 (New): The compound according to claim 22, selected from:

3-anilino-5-(furan-3-ylmethylthio)-1,2,4-triazole;
3-anilino-5-(furan-2-ylmethylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole; and
or a pharmaceutically acceptable salt or solvate thereof.

Claim 25 (New): The compound according to claim 22, selected from:

3-(2-isopropyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 26 (New): A pharmaceutical composition comprising the compound according to claim 22 and a pharmaceutically acceptable carrier.


Claim 27 (New): A pharmaceutical composition comprising the compound according to claim 23 and a pharmaceutically acceptable carrier.

Claim 28 (New): A pharmaceutical composition comprising the compound according to claim 24 and a pharmaceutically acceptable carrier.


Claim 29 (New): A pharmaceutical composition comprising the compound according to claim 25 and a pharmaceutically acceptable carrier.

Claim 30 (New): A method of making the compound of Formula (I) according to claim 22, wherein X is sulfur, comprising the steps of:


a) combining an isothiocyanate of Formula (II):




with thiourea to provide a compound of Formula (III):




b) treating the compound of Formula (III) with an alkyl halide under basic conditions to provide a compound of Formula (IV):




c) treating the compound of formula (IV) with hydrazine to provide a compound of Formula (V):




d) treating the compound of formula (V) with an alkyl halide under basic conditions to provide a compound of Formula (VI):



e) protecting the compound of formula (VI) to provide a compound of Formula (VII):



f) alkylating the compound of formula (VII) with an alkyl halide to provide a compound of Formula (VIII):



g) deprotecting the compound of formula (VIII) to provide the compound of Formula (I).

Claim 31 (New): A method of inhibiting MetAP2, comprising contacting MetAP2 with the compound of Formula (IA) according to claim 22 or a pharmaceutically acceptable salt or solvate thereof: